Sunshine Biopharma’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells

A Potential Multi-Billion Dollar Global Market Opportunity for Cancer Treatments

Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a biopharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that two of its newly designed mRNA molecules are effective at destroying cancer cells grown in culture.

The cytotoxicity tests were performed on a variety of cancer cells including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Toxicity studies using non-transformed (normal) human cells (HMEC cells) showed that these mRNA molecules had little or no cytotoxic effects. These new mRNA molecules are readily adaptable for delivery into patients using the mRNA vaccine technology. The Company anticipates filing a patent application in connection with these results soon.

“We are delighted by these findings in connection with our ongoing mRNA-as-therapeutic-agents research,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “The potential use of mRNA to treat cancer opens the door to many possibilities for patients including convenience, reduced toxicity and enhanced efficacy,“ he added.

About Sunshine Biopharma

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 6.1 million people worldwide since it first appeared in December 2019. Sunshine Biopharma is working on the development of a treatment for COVID-19 and has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. In addition, the Company recently expanded its research efforts into finding other PLpro inhibitors by entering into a collaboration agreement with the University of Arizona. The collaboration is focused on determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors, followed by efficacy testing in mice infected with SARS-CoV-2. The Company

holds the first option to negotiate for a commercial, royalty-bearing license for all intellectual property developed by University of Arizona under the research project.

In addition to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development of Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

Cautionary Note Regarding Forward Looking Statements

This press release and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “could”, “expects”, “projects,” “intends”, “plans”, “believes”, “predicts”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements appear in a number of places in this release and include all statements that are not statements of historical fact. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the Company’s control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in the Company’s filings with the SEC. The Company’s SEC filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Sunshine Biopharma, Inc. (the “Company”) expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.

For Additional Information:

Sunshine Biopharma Media Contacts: TraDigital IR
Direct Line: 917-633-8980 [email protected]

Sunshine Biopharma Inc. Contacts: Camille Sebaaly, CFO
Direct Line: 514-814-0464 [email protected] www.sunshinebiopharma.com

Sunshine Biopharma, Inc. Announces Closing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market

MONTREAL, Canada, Feb. 17, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc.

(NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical
company focused on the research, development and commercialization of oncology and antiviral
drugs, announced today the closing of its underwritten public offering of 1,882,353 units at a price
to the public of $4.25 per unit, for aggregate gross proceeds of $8 million, prior to deducting
underwriting discounts, commissions and other estimated offering expenses. Each unit consists of
one share of common stock, par value $0.001 per share, and two warrants, each warrant exercisable
for one share of common stock with an exercise price of $4.25.

In addition, the Company has granted Aegis Capital Corp. (“Aegis”) a 45-day option to purchase
additional shares of common pharmaceutical stock and/or warrants equal up to 15% of the number of shares and
warrants, respectively, sold in the offering solely to cover over-allotments, if any. The underwriter
partially exercised its over-allotment option with respect to 337,494 warrants to purchase shares of
common stock. At the closing, the Company issued an aggregate of 1,882,353 common shares and
4,102,200 warrants to purchase common shares.

The Company’s common stock and warrants are listed on the Nasdaq Capital under the symbols
“SBFM” and “SBFMW”, respectively.

Aegis Capital Corp. acted as sole book-running manager for the offering.
A registration statement on Form S-1 (No. 333-259394) relating to the securities being sold in this
offering was declared effective by the Securities and Exchange Commission (the “SEC”) on
February 14, 2022. The offering has been made only by means of a prospectus. Copies of the final
prospectus may be obtained on the SEC’s website, www.sec.gov, or by contacting Aegis Capital
Corp., Attention: Syndicate Department, 810 7th Avenue, 18th Floor, New York, NY 10019, by
email at [email protected], or by telephone at (212) 813-1010.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall
there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or
sale would be unlawful prior to registration or qualification under the securities laws of any such
state or jurisdiction.

About Sunshine Biopharma
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the
ongoing COVID-19 pandemic that has claimed the lives of over 5.3 million people worldwide since
it first appeared in December 2019. There are currently no drugs that can effectively arrest
replication of the virus in people who have contracted the illness. Sunshine Biopharma has
completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead
compound, SBFM-PL4. The Company is currently advancing the development of SBFM-PL4 in
collaboration with the University of Georgia, College of Pharmacy.

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date
have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells,
including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine
Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill
University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all
patents and intellectual property pertaining to Adva-27a.

Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements which are based on current expectations,
forecasts, and assumptions that involve risks as well as uncertainties that could cause actual
outcomes and results to differ materially from those anticipated or expected. These statements
appear in a number of places in this release and include all statements that are not statements of
historical fact regarding the intent, belief or current expectations of the Company, including
statements related to our financial performance and future growth. These risks and uncertainties are
further defined in filings and reports by the Company with the U.S. Securities and Exchange
Commission (SEC). Actual results and the timing of certain events could differ materially from
those projected in or contemplated by the forward-looking statements due to a number of factors
detailed from time to time in our filings with the SEC. Reference is hereby made to cautionary
statements and risk factors set forth in the Company’s most recent SEC filings.

For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com

Sunshine Biopharma Inc. Announces Pricing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market

MONTREAL, Canada, Feb. 15, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc.
(NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a biopharmaceutical
company focused on the research, development and commercialization of oncology and antiviral
drugs, announced today the pricing of its underwritten public offering of 1,882,353 units at a price
to the public of $4.25 per unit, for aggregate gross proceeds of $8 million, prior to deducting
underwriting discounts, commissions and other estimated offering expenses. Each unit consists of
one share of common stock, par value $0.001 per share, and two warrants, each warrant exercisable
for one share of common stock. The common stock and warrants are immediately separable from
the Units and will be issued separately. The warrants are exercisable immediately, expire five years
from the date of issuance and have an exercise price of $4.25.

In addition, the Company has granted Aegis Capital Corp. (“Aegis”) a 45-day option to purchase
additional shares of common stock and/or warrants equal up to 15% of the number of shares and
warrants, respectively, sold in the offering solely to cover over-allotments, if any. The purchase price
to be paid per additional share of common stock will be equal to the public offering price of one
unit (in each case, less $0.01 allocated to the warrants), less the underwriting discount. The purchase
price to be paid per additional warrant will be $0.01. If Aegis exercises the option to purchase only
such warrants, additional proceeds will be nominal. If Aegis exercises the option in full for common
stock and warrants, the total gross proceeds of the offering including the overallotment are expected
to be approximately $9.2 million before deducting underwriting discounts and commissions and
offering expenses. The offering is expected to close on or about February 17, 2022, subject to
customary closing conditions.

The Company also announced that, in connection with the offering, its common stock and warrants
have been approved for listing on the Nasdaq Capital Market and will begin trading on the Nasdaq
Capital Market under the symbols “SBFM” and “SBFMW” on February 15, 2022.
Aegis Capital Corp. is acting as sole book-running manager for the offering.
A registration statement on Form S-1 (No. 333-259394) relating to the securities being sold in this
offering was declared effective by the Securities and Exchange Commission (the “SEC”) on
February 14, 2022. The offering is being made only by means of a prospectus. Copies of the final
prospectus may be obtained, when available, on the SEC’s website, www.sec.gov, or by contacting
Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th Floor, New York, NY
10019, by email at [email protected], or by telephone at (212) 813-1010.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall
there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or
sale would be unlawful prior to registration or qualification under the securities laws of any such
state or jurisdiction.

About Sunshine Biopharma
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the
ongoing COVID-19 pandemic that has claimed the lives of over 5.3 million people worldwide since
it first appeared in December 2019. There are currently no drugs that can effectively arrest
replication of the virus in people who have contracted the illness. Sunshine Biopharma has
completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead
compound, SBFM-PL4. The Company is currently advancing the development of SBFM-PL4 in
collaboration with the University of Georgia, College of Pharmacy.

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date
have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells,
including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine
Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill
University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all
patents and intellectual property pertaining to Adva-27a.

Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements which are based on current expectations,
forecasts, and assumptions that involve risks as well as uncertainties that could cause actual
outcomes and results to differ materially from those anticipated or expected. These statements
appear in a number of places in this release and include all statements that are not statements of
historical fact regarding the intent, belief or current expectations of the Company, including
statements related to the closing of the offering, our financial performance, and future growth.
These risks and uncertainties are further defined in filings and reports by the Company with the U.S.
Securities and Exchange Commission (SEC). Actual results and the timing of certain events could
differ materially from those projected in or contemplated by the forward-looking statements due to
a number of factors detailed from time to time in our filings with the SEC. Reference is hereby
made to cautionary statements and risk factors set forth in the Company’s most recent SEC filings.

For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
[email protected]
www.sunshinebiopharma.com

What Are Bio Pharmaceuticals And Why Do Our Bodies Need Them?

Since their development, biopharmaceuticals have enhanced the quality of life in patients with various diseases. They can also help replenish the amino acids and vitamins we need from our diets but don’t always get in the proper doses. Amino acids are organic compounds that help to break down your food into the fuel you need. In this article, we take a closer look at what biopharmaceuticals are and how they can fuel our bodies to keep up with the demands of daily living.

BIO PHARMACEUTICALS VS REGULAR PHARMACEUTICALS

In broad terms, biopharmaceuticals are defined as pharmaceuticals that are inherently biological and produced using biotechnology. Their structure is identical to compounds already found in nature. They contain live entities and can include proteins, DNA  RNA, or antisense oligonucleotides for therapeutic purposes. However, they can be challenging to manufacture and require specialized and expensive processing and purification methods. In short, biopharmaceuticals are derived from living organisms. In contrast, pharmaceutical drugs are made from chemicals and synthetic processes rather than natural ones.

WHY BIO IS BETTER FOR OUR BODIES

One of the benefits of biopharmaceuticals is that they provide targeted treatment with fewer side effects, devoid of chemicals. Patients with cancer, diabetes, cardiovascular disease, immune diseases, and other health problems benefit from this. Being healthy requires a balanced diet, physical activity, and general wellness. Amino acids are organic compounds that help to fuel us by breaking down our food and building proteins. Vitamins and minerals also help with healthy bodily functions and boost our immune systems, as well as repairing cell damage. Since our bodies cannot produce these amino acids and vitamins, biopharmaceuticals are a great source of these essential nutrients.

Ideally, a healthy diet should provide everything our bodies need, but it doesn’t always happen that way, as time, stress and resources sometimes prevent us from eating well. Even if we manage to eat balanced meals from time to time, there may still be some shortfall, which would have to be replaced with a supplement. Illnesses can also drain us of energy and affect our appetites, so biopharmaceutical products provide a safe alternative for the missing nutrients with little to no side effects.

GIVE YOUR BODY THE FUEL IT NEEDS.

Whether you want to boost your immune system, increase your protein intake and build muscle, or explore meal replacement options, Sunshine Biopharma Nutrition has the solution. All of our products are backed by science. We are continually engaged in the development and commercialization of science-based nutritional supplements. For a healthy dietary supplement, contact us here or call 514-426-6161.